BI 655088

Drug Profile

BI 655088

Alternative Names: Anti-CX3CR1 Nanobody®; BI655088

Latest Information Update: 01 Jun 2016

Price : $50

At a glance

  • Originator Ablynx
  • Developer Ablynx; Boehringer Ingelheim
  • Class Proteins
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Kidney disorders

Most Recent Events

  • 31 May 2016 Boehringer Ingelheim suspends enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02696616)
  • 21 Apr 2016 Phase-I clinical trials in Kidney disorders (In volunteers) in Belgium (IV)
  • 01 Feb 2016 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Belgium (NCT02696616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top